Levi Garraway, Roche's chief medical officer and head of global product development. Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback